Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129


Omega-3 fatty acid supplementation in adolescents with borderline personality disorder and ultra-high risk criteria for psychosis: a post hoc subgroup analysis of a double-blind, randomized controlled trial.

Amminger GP, Chanen AM, Ohmann S, Klier CM, Mossaheb N, Bechdolf A, Nelson B, Thompson A, McGorry PD, Yung AR, Schäfer MR.

Can J Psychiatry. 2013 Jul;58(7):402-8.


Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

Amminger GP, Schäfer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE.

Arch Gen Psychiatry. 2010 Feb;67(2):146-54. doi: 10.1001/archgenpsychiatry.2009.192.


Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.

McGorry PD, Nelson B, Markulev C, Yuen HP, Schäfer MR, Mossaheb N, Schlögelhofer M, Smesny S, Hickie IB, Berger GE, Chen EY, de Haan L, Nieman DH, Nordentoft M, Riecher-Rössler A, Verma S, Thompson A, Yung AR, Amminger GP.

JAMA Psychiatry. 2017 Jan 1;74(1):19-27. doi: 10.1001/jamapsychiatry.2016.2902.


Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids.

Amminger GP, Mechelli A, Rice S, Kim SW, Klier CM, McNamara RK, Berk M, McGorry PD, Schäfer MR.

Transl Psychiatry. 2015 Jan 13;5:e495. doi: 10.1038/tp.2014.134.


Supplementation of n-3 Polyunsaturated Fatty Acids for Major Depressive Disorder: A Randomized, Double-Blind, 12-Week, Placebo-Controlled Trial in Korea.

Park Y, Park YS, Kim SH, Oh DH, Park YC.

Ann Nutr Metab. 2015;66(2-3):141-8. doi: 10.1159/000377640. Epub 2015 Mar 24.


Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: when do they begin to be effective?

Mossaheb N, Schäfer MR, Schlögelhofer M, Klier CM, Cotton SM, McGorry PD, Amminger GP.

Schizophr Res. 2013 Aug;148(1-3):163-7. doi: 10.1016/j.schres.2013.05.027. Epub 2013 Jun 15.


Omega-3 fatty acid supplementation changes intracellular phospholipase A2 activity and membrane fatty acid profiles in individuals at ultra-high risk for psychosis.

Smesny S, Milleit B, Hipler UC, Milleit C, Schäfer MR, Klier CM, Holub M, Holzer I, Berger GE, Otto M, Nenadic I, Berk M, McGorry PD, Sauer H, Amminger GP.

Mol Psychiatry. 2014 Mar;19(3):317-24. doi: 10.1038/mp.2013.7. Epub 2013 Mar 12.


A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study.

Zanarini MC, Schulz SC, Detke HC, Tanaka Y, Zhao F, Lin D, Deberdt W, Kryzhanovskaya L, Corya S.

J Clin Psychiatry. 2011 Oct;72(10):1353-62. doi: 10.4088/JCP.08m04138yel.


A randomized clinical trial of high eicosapentaenoic acid omega-3 fatty acids and inositol as monotherapy and in combination in the treatment of pediatric bipolar spectrum disorders: a pilot study.

Wozniak J, Faraone SV, Chan J, Tarko L, Hernandez M, Davis J, Woodworth KY, Biederman J.

J Clin Psychiatry. 2015 Nov;76(11):1548-55. doi: 10.4088/JCP.14m09267. Erratum in: J Clin Psychiatry. 2016 Sep;77(9):e1153.


A randomised, double-blind, placebo-controlled trial of minocycline and/or omega-3 fatty acids added to treatment as usual for at-risk mental states (NAYAB): study protocol.

Qurashi I, Chaudhry IB, Khoso AB, Farooque S, Lane S, Husain MO, Chu S, Sarginson J, Hamarani M, Naqvi HA, Razzaque B, Minhas FA, Yung AR, Deakin JFW, Husain N.

Trials. 2017 Nov 9;18(1):524. doi: 10.1186/s13063-017-2275-y.


A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia.

Bentsen H, Osnes K, Refsum H, Solberg DK, Bøhmer T.

Transl Psychiatry. 2013 Dec 17;3:e335. doi: 10.1038/tp.2013.110.


The efficacy of omega-3 supplementation for major depression: a randomized controlled trial.

Lespérance F, Frasure-Smith N, St-André E, Turecki G, Lespérance P, Wisniewski SR.

J Clin Psychiatry. 2011 Aug;72(8):1054-62. doi: 10.4088/JCP.10m05966blu. Epub 2010 Jun 15.


Relationship between Erythrocyte Fatty Acid Composition and Psychopathology in the Vienna Omega-3 Study.

Kim SW, Jhon M, Kim JM, Smesny S, Rice S, Berk M, Klier CM, McGorry PD, Schäfer MR, Amminger GP.

PLoS One. 2016 Mar 10;11(3):e0151417. doi: 10.1371/journal.pone.0151417. eCollection 2016.


Reduction in triglyceride level with N-3 polyunsaturated fatty acids in HIV-infected patients taking potent antiretroviral therapy: a randomized prospective study.

De Truchis P, Kirstetter M, Perier A, Meunier C, Zucman D, Force G, Doll J, Katlama C, Rozenbaum W, Masson H, Gardette J, Melchior JC.

J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):278-85.


Effect of omega-3 fatty acid-containing phospholipids on blood catecholamine concentrations in healthy volunteers: a randomized, placebo-controlled, double-blind trial.

Hamazaki K, Itomura M, Huan M, Nishizawa H, Sawazaki S, Tanouchi M, Watanabe S, Hamazaki T, Terasawa K, Yazawa K.

Nutrition. 2005 Jun;21(6):705-10.


Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial.

Arnold C, Winter L, Fröhlich K, Jentsch S, Dawczynski J, Jahreis G, Böhm V.

JAMA Ophthalmol. 2013 May;131(5):564-72. doi: 10.1001/jamaophthalmol.2013.2851.


NEURAPRO-E study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders.

Markulev C, McGorry PD, Nelson B, Yuen HP, Schaefer M, Yung AR, Thompson A, Berger G, Mossaheb N, Schlögelhofer M, Smesny S, de Haan L, Riecher-Rössler A, Nordentoft M, Chen EYH, Verma S, Hickie I, Amminger GP.

Early Interv Psychiatry. 2017 Oct;11(5):418-428. doi: 10.1111/eip.12260. Epub 2015 Aug 16.


Supplemental Content

Support Center